Targeted Therapies in Breast Cancer

Spiral Bound | September 22, 2011

byHarold J. Burstein

not yet rated|write a review
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatmentof breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex,targeting the ER specifically in breast cancer cells), and letrozole (Femara, targeting the aromatose pathway), raloxifene (Evista, a selective estrogen receptor modulator), ixabepilone (Ixempra, a -tubulin inhibitor) have also been approved for various stages and specific settings in breast cancertreatment. The current challenges in the field include further targeting of these agents as part of specific strategies for each patient (biomarker testing, pharmacogenetics, etc.), as well as follow-up and management of adverse events.Part of the Oxford American Pocket Notes series, this volume provides clinicians with the ultra-concise, evidence-based, current information and insight on implementing the latest treatment strategies, including targeted agents, into clinical practice. This portable volume is intended to providequick, easily accessible guidance for the practicing oncologist, oncology care staff (including nurses and PAs) as well as the primary care practitioner, on the mechanism of action, dosing and administration and adverse effects of the approved targeted agents.

Pricing and Purchase Info

$19.95

Ships within 1-3 weeks
Ships free on orders over $25

From the Publisher

The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatmentof breast cancer, such as trastuzamab (Hercep...

Harold J. Burstein, MD, PhD, is Associate Professor of Medicine at the Dana Farber Cancer Institute Breast Oncology Center at Harvard Medical School in Boston, MA.

other books by Harold J. Burstein

Format:Spiral BoundDimensions:64 pages, 3.7 × 6.69 × 0.31 inPublished:September 22, 2011Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199735670

ISBN - 13:9780199735679

Look for similar items by category:

Customer Reviews of Targeted Therapies in Breast Cancer

Reviews

Extra Content

Table of Contents

1. Introduction (epidemiology, molecular pathways)2. Diagnosis and classification (pathological status, biomarkers (HER-2, EGFR, etc.), ER - includes discussion on triple negative status)3. Key clinical studies4. Approaches to treatment - mechanisms of action of available inhibitors angiogenesis agents, patient selection (tools and algorithms), sequencing of agents, adverse effects, follow-up and management5. Triple negative disease and other challenges6. Emerging therapeutic targets in breast cancer (i.e. Src, cell cycle, mTOR, TNF, etc.)7. Dosing and administration guidelines for currently approved agents8. Provider and patient resources9. References